



## OPEN ACCESS

EDITED AND REVIEWED BY  
Aljoscha Thomschewski,  
University Hospital Salzburg, Austria

\*CORRESPONDENCE  
Zubeda Sheikh  
✉ zubeda.sheikh@vcuhealth.org  
Lawrence J. Hirsch  
✉ lawrence.hirsch@yale.edu

†PRESENT ADDRESS  
Zubeda Sheikh,  
Department of Neurology, Virginia  
Commonwealth University, Richmond, VA,  
United States

RECEIVED 10 October 2024  
ACCEPTED 15 October 2024  
PUBLISHED 11 November 2024

CITATION  
Sheikh Z and Hirsch LJ (2024) Corrigendum: A  
practical approach to in-hospital  
management of new-onset refractory status  
epilepticus/febrile infection related epilepsy  
syndrome. *Front. Neurol.* 15:1509148.  
doi: 10.3389/fneur.2024.1509148

COPYRIGHT  
© 2024 Sheikh and Hirsch. This is an  
open-access article distributed under the  
terms of the [Creative Commons Attribution  
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or  
reproduction in other forums is permitted,  
provided the original author(s) and the  
copyright owner(s) are credited and that the  
original publication in this journal is cited, in  
accordance with accepted academic practice.  
No use, distribution or reproduction is  
permitted which does not comply with these  
terms.

# Corrigendum: A practical approach to in-hospital management of new-onset refractory status epilepticus/febrile infection related epilepsy syndrome

Zubeda Sheikh<sup>1,2\*†</sup> and Lawrence J. Hirsch<sup>2\*</sup>

<sup>1</sup>Department of Neurology, West Virginia University School of Medicine, Morgantown, WV, United States, <sup>2</sup>Epilepsy Division, Department of Neurology, Yale School of Medicine, New Haven, CT, United States

## KEYWORDS

new-onset refractory status epilepticus, febrile infection related epilepsy syndrome, anakinra, tocilizumab, rituximab, super-refractory status epilepticus, neuroinflammation, autoimmune encephalitis

## A Corrigendum on

[A practical approach to in-hospital management of new-onset refractory status epilepticus/febrile infection related epilepsy syndrome](#)

by Sheikh, Z., and Hirsch, L. J. (2023). *Front. Neurol.* 14:1150496.  
doi: 10.3389/fneur.2023.1150496


In the published article, there was an error in [Figure 1](#) as published. The dose of IVIG was listed as 2 mg/kg over 2–5 days, when it should be 2 g/kg over 2–5 days.

The corrected [Figure 1](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



**FIGURE 1** Flow diagram for evaluation and management of NORSE/FIRES. NORSE, New Onset Refractory Status Epilepticus; FIRES, Febrile infection-related epilepsy syndrome; SE, Status epilepticus; RSE, Refractory status epilepticus; GAD, Gadolinium; MRV, Magnetic resonance venogram; MRA, Magnetic resonance angiography; CEEG, Continuous EEG; USG, Ultrasonography; PET, Positron emission tomography; HSV, Herpes simplex virus; VNS, Vagus nerve stimulator.   Diagnostic consideration.   Diagnostic procedure.   Treatment.   Outcome assessment.   Management timeline.